Abbott Laboratories vs. Spyre Therapeutics, Inc. Common Stock
Abbott Laboratories and Spyre Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | SYRE | |
|---|---|---|
| Market Cap | $197.44 billion | $8.25 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | SYRE | |
|---|---|---|
| P/E Ratio | 36.93 | — |
| Price / Book | 3.81 | — |
| Price / Sales | 4.24 | — |
ABT and SYRE split the valuation factors evenly.
Profitability
| ABT | SYRE | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and SYRE split the profitability factors evenly.
Dividend
| ABT | SYRE | |
|---|---|---|
| Dividend Yield | 2.21% | — |
| Payout Ratio | 81.55 | — |
ABT and SYRE split the dividend factors evenly.
Risk & Sentiment
| ABT | SYRE | |
|---|---|---|
| Short Interest | 0.57% | 0.23% |
SYRE leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, SYRE overview, SYRE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.